These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 21456006

  • 1. Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor.
    Sawaki A, Nishida T, Doi T, Yamada Y, Komatsu Y, Kanda T, Kakeji Y, Onozawa Y, Yamasaki M, Ohtsu A.
    Cancer; 2011 Oct 15; 117(20):4633-41. PubMed ID: 21456006
    [Abstract] [Full Text] [Related]

  • 2. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
    Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, Town A, McKinley A, Ou WB, Fletcher JA, Fletcher CD, Huang X, Cohen DP, Baum CM, Demetri GD.
    J Clin Oncol; 2008 Nov 20; 26(33):5352-9. PubMed ID: 18955458
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib.
    Cauchi C, Somaiah N, Engstrom PF, Litwin S, Lopez M, Lee J, Davey M, Bove B, von Mehren M.
    Cancer Chemother Pharmacol; 2012 Apr 20; 69(4):977-82. PubMed ID: 22119758
    [Abstract] [Full Text] [Related]

  • 4. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.
    Reichardt P, Blay JY, Gelderblom H, Schlemmer M, Demetri GD, Bui-Nguyen B, McArthur GA, Yazji S, Hsu Y, Galetic I, Rutkowski P.
    Ann Oncol; 2012 Jul 20; 23(7):1680-7. PubMed ID: 22357255
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors.
    Li J, Gao J, Hong J, Shen L.
    Future Oncol; 2012 May 20; 8(5):617-24. PubMed ID: 22646775
    [Abstract] [Full Text] [Related]

  • 6. Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.
    Yoon DH, Ryu MH, Ryoo BY, Beck M, Choi DR, Cho Y, Lee JL, Chang HM, Kim TW, Kang YK.
    Invest New Drugs; 2012 Apr 20; 30(2):819-27. PubMed ID: 21104107
    [Abstract] [Full Text] [Related]

  • 7. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
    Janeway KA, Albritton KH, Van Den Abbeele AD, D'Amato GZ, Pedrazzoli P, Siena S, Picus J, Butrynski JE, Schlemmer M, Heinrich MC, Demetri GD.
    Pediatr Blood Cancer; 2009 Jul 20; 52(7):767-71. PubMed ID: 19326424
    [Abstract] [Full Text] [Related]

  • 8. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.
    Wu L, Zhang Z, Yao H, Liu K, Wen Y, Xiong L.
    Drug Des Devel Ther; 2014 Jul 20; 8():2061-7. PubMed ID: 25378911
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.
    Ganjoo KN, Villalobos VM, Kamaya A, Fisher GA, Butrynski JE, Morgan JA, Wagner AJ, D'Adamo D, McMillan A, Demetri GD, George S.
    Ann Oncol; 2014 Jan 20; 25(1):236-40. PubMed ID: 24356634
    [Abstract] [Full Text] [Related]

  • 12. Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability.
    Kim KP, Ryu MH, Yoo C, Ryoo BY, Choi DR, Chang HM, Lee JL, Beck MY, Kim TW, Kang YK.
    Cancer Chemother Pharmacol; 2011 Aug 20; 68(2):285-91. PubMed ID: 20957481
    [Abstract] [Full Text] [Related]

  • 13. [Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib].
    Hong JL, Li J, Li J, Shen L.
    Zhonghua Bing Li Xue Za Zhi; 2012 Jun 20; 41(6):386-90. PubMed ID: 22932406
    [Abstract] [Full Text] [Related]

  • 14. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor.
    Prior JO, Montemurro M, Orcurto MV, Michielin O, Luthi F, Benhattar J, Guillou L, Elsig V, Stupp R, Delaloye AB, Leyvraz S.
    J Clin Oncol; 2009 Jan 20; 27(3):439-45. PubMed ID: 19064982
    [Abstract] [Full Text] [Related]

  • 15. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A, Boglione A.
    Recenti Prog Med; 2015 Jan 20; 106(1):17-22. PubMed ID: 25621775
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.
    George S, Wang Q, Heinrich MC, Corless CL, Zhu M, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Tap WD, Yap JT, Van den Abbeele AD, Manola JB, Solomon SM, Fletcher JA, von Mehren M, Demetri GD.
    J Clin Oncol; 2012 Jul 01; 30(19):2401-7. PubMed ID: 22614970
    [Abstract] [Full Text] [Related]

  • 17. [Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
    Italiano A, Bui B.
    Bull Cancer; 2008 Jan 01; 95(1):107-16. PubMed ID: 18230576
    [Abstract] [Full Text] [Related]

  • 18. Gastrointestinal stromal tumors.
    Antonescu C.
    Curr Top Microbiol Immunol; 2012 Jan 01; 355():41-57. PubMed ID: 22015552
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
    Prenen H, Cools J, Mentens N, Folens C, Sciot R, Schöffski P, Van Oosterom A, Marynen P, Debiec-Rychter M.
    Clin Cancer Res; 2006 Apr 15; 12(8):2622-7. PubMed ID: 16638875
    [Abstract] [Full Text] [Related]

  • 20. Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors.
    Gao J, Tian Y, Li J, Sun N, Yuan J, Shen L.
    Med Oncol; 2013 Jun 15; 30(2):522. PubMed ID: 23456621
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.